BR112020021255A2 - formulações tamponadas de bevacizumabe para uso no tratamento de doenças - Google Patents
formulações tamponadas de bevacizumabe para uso no tratamento de doenças Download PDFInfo
- Publication number
- BR112020021255A2 BR112020021255A2 BR112020021255-5A BR112020021255A BR112020021255A2 BR 112020021255 A2 BR112020021255 A2 BR 112020021255A2 BR 112020021255 A BR112020021255 A BR 112020021255A BR 112020021255 A2 BR112020021255 A2 BR 112020021255A2
- Authority
- BR
- Brazil
- Prior art keywords
- formulation
- antibody
- use according
- respects
- fact
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Ophthalmology & Optometry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862658772P | 2018-04-17 | 2018-04-17 | |
| US62/658,772 | 2018-04-17 | ||
| US201862776686P | 2018-12-07 | 2018-12-07 | |
| US62/776,686 | 2018-12-07 | ||
| PCT/US2019/027790 WO2019204380A1 (en) | 2018-04-17 | 2019-04-17 | Buffered formulations of bevacizumab for use of treating diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112020021255A2 true BR112020021255A2 (pt) | 2021-02-02 |
Family
ID=66429576
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112020021255-5A BR112020021255A2 (pt) | 2018-04-17 | 2019-04-17 | formulações tamponadas de bevacizumabe para uso no tratamento de doenças |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20210230261A1 (https=) |
| EP (1) | EP3781199A1 (https=) |
| JP (1) | JP2021522180A (https=) |
| KR (1) | KR20210011923A (https=) |
| CN (1) | CN112543645A (https=) |
| AU (1) | AU2019256289A1 (https=) |
| BR (1) | BR112020021255A2 (https=) |
| CA (1) | CA3097123A1 (https=) |
| IL (1) | IL278041A (https=) |
| MX (1) | MX2020010968A (https=) |
| SG (1) | SG11202010178XA (https=) |
| WO (1) | WO2019204380A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| KR102799807B1 (ko) | 2015-12-30 | 2025-04-24 | 코디악 사이언시스 인코포레이티드 | 항체 및 이의 접합체 |
| MX2020009152A (es) | 2018-03-02 | 2020-11-09 | Kodiak Sciences Inc | Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos. |
| KR102735988B1 (ko) | 2019-02-18 | 2024-12-03 | 일라이 릴리 앤드 캄파니 | 치료 항체 제제 |
| CN118718181A (zh) | 2019-06-05 | 2024-10-01 | 里珍纳龙药品有限公司 | 用于精确剂量递送的装置及方法 |
| CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| KR20220149690A (ko) * | 2020-03-04 | 2022-11-08 | 상하이 헨리우스 바이오테크, 인크. | 베바시주맙을 포함하는 약물 조제용 제제 |
| CN113546172A (zh) * | 2020-04-24 | 2021-10-26 | 山东大学齐鲁医院 | Vegf抑制剂在制备治疗缺氧相关疾病药物中的应用 |
| WO2022006091A1 (en) * | 2020-06-29 | 2022-01-06 | Anovent Pharmaceutical (U.S.), Llc | Biopharmaceutical formulation of anti-pd-1, anti-pd-l1, and anti-vegfr therapeutic monoclonal antibodies and method for treating nsclc by inhalation |
| USD1120314S1 (en) | 2022-11-30 | 2026-03-24 | Regeneron Pharmaceuticals, Inc. | Dose delivery device |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11078262B2 (en) * | 2007-04-30 | 2021-08-03 | Allergan, Inc. | High viscosity macromolecular compositions for treating ocular conditions |
| US8821870B2 (en) * | 2008-07-18 | 2014-09-02 | Allergan, Inc. | Method for treating atrophic age related macular degeneration |
| EP3861969A1 (en) * | 2010-08-05 | 2021-08-11 | ForSight Vision4, Inc. | Injector apparatus for drug delivery |
| MX379491B (es) * | 2014-06-28 | 2025-03-10 | Kodiak Sciences Inc | Antagonistas duales de factor de crecimiento derivado de plaquetas (pdgf)/factor de crecimiento endotelial vascular (vegf) |
| AU2016382786A1 (en) * | 2015-12-29 | 2018-07-19 | Outlook Therapeutics, Inc. | Buffered formulations of bevacizumab |
| CN106924184B (zh) * | 2017-03-29 | 2020-07-17 | 烟台大学 | 一种眼部玻璃体注射用多囊脂质体及其制备方法 |
-
2019
- 2019-04-17 KR KR1020207033144A patent/KR20210011923A/ko not_active Abandoned
- 2019-04-17 MX MX2020010968A patent/MX2020010968A/es unknown
- 2019-04-17 US US17/048,107 patent/US20210230261A1/en not_active Abandoned
- 2019-04-17 BR BR112020021255-5A patent/BR112020021255A2/pt unknown
- 2019-04-17 CA CA3097123A patent/CA3097123A1/en active Pending
- 2019-04-17 WO PCT/US2019/027790 patent/WO2019204380A1/en not_active Ceased
- 2019-04-17 JP JP2020557256A patent/JP2021522180A/ja active Pending
- 2019-04-17 SG SG11202010178XA patent/SG11202010178XA/en unknown
- 2019-04-17 AU AU2019256289A patent/AU2019256289A1/en not_active Abandoned
- 2019-04-17 EP EP19722351.4A patent/EP3781199A1/en not_active Withdrawn
- 2019-04-17 CN CN201980040536.7A patent/CN112543645A/zh active Pending
-
2020
- 2020-10-14 IL IL278041A patent/IL278041A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021522180A (ja) | 2021-08-30 |
| CA3097123A1 (en) | 2019-10-24 |
| CN112543645A (zh) | 2021-03-23 |
| MX2020010968A (es) | 2021-01-08 |
| EP3781199A1 (en) | 2021-02-24 |
| US20210230261A1 (en) | 2021-07-29 |
| IL278041A (en) | 2020-11-30 |
| AU2019256289A1 (en) | 2020-11-12 |
| SG11202010178XA (en) | 2020-11-27 |
| WO2019204380A1 (en) | 2019-10-24 |
| KR20210011923A (ko) | 2021-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112020021255A2 (pt) | formulações tamponadas de bevacizumabe para uso no tratamento de doenças | |
| RU2722643C2 (ru) | Способ лечения болезней глаз | |
| EP3397281B1 (en) | Buffered formulations of bevacizumab | |
| CN102340991B (zh) | 向眼部递送受体酪氨酸激酶抑制性(RTKi)化合物的药物组合物 | |
| CN121421956A (zh) | 含有高浓度vegf受体融合蛋白的制剂 | |
| JP2024042697A (ja) | 眼疾患を治療するための方法 | |
| US20220251210A1 (en) | Formulation comprising anti-cd47/pd-l1 bispecific antibody, method for preparing same and use thereof | |
| KR20260025887A (ko) | 익상편을 치료하기 위한 조성물 및 방법 | |
| JP7089121B2 (ja) | 高濃度の抗ｖｅｇｆ抗体を含有するタンパク質溶液製剤 | |
| JP2013136588A (ja) | ＩＬ−１ｒａの凝集を低下させる方法 | |
| JP7828274B2 (ja) | 眼疾患を治療するための方法 | |
| CN121285391A (zh) | 聚唾液酸-聚合物缀合物和纳米颗粒 | |
| US20130017197A1 (en) | Stabilized antibody preparations and uses thereof | |
| US20220251188A1 (en) | Formulation comprising anti-lag-3 antibody, method for preparing same and use thereof | |
| WO2023202685A1 (en) | Pharmaceutical compositons containing anti-her2 antibody for subcutaneous administration | |
| Sergeys et al. | SRC INHIBITION AS POTENTIAL TREATMENT STRATEGY FOR DIABETIC RETINOPATHY | |
| CN121194795A (zh) | 膜联蛋白a5蛋白质与抗vegf药剂作为组合疗法用于治疗黄斑水肿或视网膜静脉阻塞 | |
| JP2026072102A (ja) | 眼疾患を治療するための方法 | |
| TW202532435A (zh) | 治療新生血管性眼疾之方法 | |
| TW202227121A (zh) | 以含有天凡諾賽普特（ｔａｎｆａｎｅｒｃｅｐｔ）之眼用組成物治療乾眼症 | |
| BR122024010134A2 (pt) | Uso de um agente anti-c5 para reduzir o crescimento de uma lesão de atrofia geográfica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |